KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today that ASMANEX(R) TWISTHALER(R) 110 mcg (mometasone furoate ...

Mometasone furoate 110mcg/inh, 220mcg/inh; pwd for oral inhalation; with dose counter. Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of ...

Mometasone furoate 50mcg, 100mcg, 200mcg; per actuation; metered-dose inhaler with dose counter. Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise ...

KENILWORTH, N.J. The Food and Drug Administration has approved Schering-Plough’s asthma inhaler Asmanex twisthaler 110 mcg for the maintenance of asthma as a preventive therapy in patients 4 to 11 ...

Schering-Plough announced that the FDA has approved Asmanex Twisthaler 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to ...

Asmanex Twisthaler has been launched by Schering-Plough as therapy in the control and management of mild, moderate or severe persistent asthma in Asmanex Twisthaler has been launched by ...

Schering-Plough and Novartis will develop a once-daily inhaled combination therapy for asthma and COPD, the firms said. The inhaler would combine mometasone, the active ingredient of Schering-Plough’s ...

FDA has approved a new inhaler therapy for children with asthma called Asmanex Twisthaler 220 mcg to be taken only once daily . FDA has approved a new inhaler therapy for children with asthma called ...

Schering-Plough and Novartis have extended their collaboration on combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The firms will combine mometasone, ...

Find clinical guidance on Asmanex HFA, including indications, dosing, safety, side effects and evidence-based insights for healthcare professionals.